PCAC, July 23–24 2026: the peptide meeting agenda
Seven peptides, two days, one advisory vote that decides nothing on its own. On July 23 the panel recommended BPC-157, KPV, TB-500 and MOTS-c for the 503A list — a recommendation, not approval. On July 24 it recommended Semax and Epitalon and rejected Emideltide/DSIP — six of seven advanced; tallies below are as reported by trade press (FDA has posted no minutes, transcript or vote-results summary). Here's the agenda, the outcome, and what actually happens next.
Last reviewed July 26, 2026 · Updated after every FDA action · Not legal or medical advice
What this meeting actually does
The Pharmacy Compounding Advisory Committee is an independent panel that advises the FDA. Over two days it reviewed whether seven peptides belong on the 503A Bulks List — the list that lets a licensed pharmacy compound a substance that has no USP monograph and isn't part of an FDA-approved drug.
On July 23, 2026 the committee voted to recommend BPC-157, KPV, TB-500 and MOTS-c for the list, and on July 24 it recommended Semax and Epitalon while rejecting Emideltide/DSIP — six of seven, all against FDA staff advice. Every tally on this page is as reported by trade press (FDA has posted no minutes, transcript or vote-results summary): reported as Semax 8–5–1 and DSIP 6–7–1, and as 7–4–1 or 7–5–1 for Epitalon depending on the outlet — most law-firm accounts report 7–4–1, ArentFox Schiff reports 7–5–1, and we do not resolve the conflict; FDA's published Final Meeting Roster lists 12 members eligible to vote on that substance. But it votes on recommendations, it does not make law. The FDA isn't bound by the outcome, and no substance reaches the list without a separate formal rulemaking process afterward, realistically into 2027. Nothing you can order changed.
The agenda
Nominators present first; open public hearing sessions run across both days.
Seven substances, fourteen nominations — each peptide is reviewed as two separate entries, free base and acetate, because salt forms can behave differently and are evaluated independently.
The details
FDA White Oak Campus, Silver Spring, Maryland. A virtual attendance option is available.
FDA-2025-N-6895 on regulations.gov. The public comment window closed July 9, 2026. Comments filed before then went to committee members ahead of the meeting.
FDA publishes its scientific briefing documents at least two business days before the meeting.
What the committee is looking at
We break down how each factor applies to BPC-157 and TB-500, and what each possible outcome would mean →
Three steps, and the vote is only the second one
The nominators withdrew their nominations and the FDA updated a website table — there was no rulemaking, no Federal Register action and no codification. FDA did not re-evaluate the substances and preserved its safety findings verbatim, which leaves them in no category at all, outside every enforcement-discretion policy. It was not approval, and it did not authorize compounding.
The committee reviewed all seven and recommended six. Advisory only. The FDA is not bound by it.
For the six recommended peptides, the FDA must open a formal rulemaking; only that can actually add a substance to the 503A list. It takes months, not days, and it is not guaranteed. Emideltide/DSIP was not recommended and is not on that path.
A second PCAC meeting for five more substances: LL-37, GHK-Cu, Dihexa, Melanotan II and PEG-MGF. Advisory review again, so the same rule holds: nothing you can order changes.
Wondering where BPC-157 stands right now? →
What we posted, and when
The meeting closed on July 24. We posted the committee's recommendation for each of the seven substances and updated every row on the status board above — including the plain-English verdict for each one. Day 1 · Day 2.
We also said plainly what the six favorable recommendations do not mean: the FDA still has to act, and nothing is orderable until a licensed clinician can prescribe it through a compliant pharmacy. We won't market any of these compounds before that's true.
Get the next status changeWhere these seven stand today
Two signals, kept separate: the regulatory status, and what it means for you.
See the full tracker and the changelog →
Compounded, not FDA-approved. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not reviewed by the FDA for safety, effectiveness, or manufacturing the way approved drugs are. They are not the same as brand-name products, and they're only appropriate when a licensed clinician determines FDA-approved options don't fit your situation.
You don't have to wait on a committee
If you came here for recovery, energy, longevity or weight, there are compounded therapies a licensed clinician can prescribe today where they're clinically appropriate — matched to your goal, your health history, and your state. Two minutes tells you what you're eligible for. Nothing to pay to find out.
Questions people ask
What is PCAC?
The Pharmacy Compounding Advisory Committee is an independent panel of scientific and medical experts that advises the FDA on bulk drug substances — the raw ingredients licensed 503A compounding pharmacies work with. It reviews evidence and makes recommendations. It doesn't make law.
Which peptides are reviewed on which day?
July 23: BPC-157, KPV, TB-500 and MOTS-c — all four recommended. July 24: Semax and Epitalon recommended, Emideltide/DSIP not recommended. Tallies are as reported by trade press (FDA has posted no minutes, transcript or vote-results summary): reported as Semax 8–5–1, Epitalon 7–4–1 by most law-firm accounts or 7–5–1 by ArentFox Schiff and DSIP 6–7–1. Each was reviewed in both free base and acetate forms.
Can I attend or submit a comment?
The meeting is public, held at FDA's White Oak Campus in Silver Spring, Maryland, with a virtual option. The written comment docket (FDA-2025-N-6895) closed on July 9, 2026, so new written comments won't reach committee members before the meeting.
Does a positive vote mean BPC-157 becomes available?
No. The recommendation is advisory and the FDA isn't bound by it. Even a positive recommendation requires a separate formal rulemaking process before a substance can be added to the 503A list — and separately, a licensed clinician has to be able to prescribe it through a compliant pharmacy before anyone should offer it to you.
When will the FDA actually decide?
There's no fixed date. Rulemaking runs on its own timeline and typically takes many months. We'll post each status change here, dated, as it happens.
What can a clinician prescribe right now?
Depending on your health history and your state, a licensed clinician may prescribe compounded semaglutide or tirzepatide, sermorelin, NAD+ and B12, among others. These are compounded and not FDA-approved. The eligibility check shows what applies to you before anyone charges you anything.